Eupraxia Pharmaceuticals (EPRX) Non-Current Debt (2022 - 2024)

Eupraxia Pharmaceuticals (EPRX) posted quarterly Non-Current Debt of $21209.0 for Q2 2024, down 49.64% quarter-over-quarter from $42112.0 in Q1 2024.

Eupraxia Pharmaceuticals (EPRX) Non-Current Debt (2022 - 2024) Analysis & Trends

Eupraxia Pharmaceuticals (EPRX) has reported Non-Current Debt for 3 consecutive years, with $21209.0 the latest figure, recorded in Q2 2024.

In Q2 2024, Non-Current Debt changed N/A year-over-year to $21209.0; the TTM figure through Jun 2024 stood at $21209.0 (changed N/A YoY), while the FY2023 annual figure was $62709.0, changed 0.0% from the prior year.
Non-Current Debt declined to $21209.0 in Q2 2024 per EPRX's latest filing, from $42112.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $62709.0 in Q4 2022 and bottomed at $21209.0 in Q2 2024.
Historically, Non-Current Debt has averaged $47184.8 across 3 years, with a median of $52410.5 in 2022.
On a YoY basis, Non-Current Debt climbed as much as 0.0% in 2023 and fell as far as 0.0% in 2023.
Eupraxia Pharmaceuticals' Non-Current Debt stood at $62709.0 in 2022, then changed by 0.0% to $62709.0 in 2023, then slumped by 66.18% to $21209.0 in 2024.
Business Quant data shows EPRX's Non-Current Debt at $21209.0 in Q2 2024, $42112.0 in Q1 2024, and $62709.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Eupraxia Pharmaceuticals	381.11 Mn	379.51 Mn	-	-

Download Data